Iván González, Medical Oncologist at the Comprehensive Cancer Center, Hospital Ángeles Puebla, shared on X:
“Breaking news from WCLC25!
A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), shows encouraging safety and efficacy in previously treated patients with EGFR-mutated NSCLC.
Iza-bren is a first-in-class EGFR x HER3 bispecific ADC linked to a novel topoisomerase I inhibitor payload (Ed-04). Evaluated in two Phase I/II studies in patients with locally advanced or metastatic solid tumors, including EGFR-mutated NSCLC.
Key results (Phase I/II, 2.5 mg/kg D1D8 Q3W):
ORR: 66%, cORR: 56%, mPFS: 12.5 mo, mDOR: 13.7 mo, 12-mo OS rate: 80.3%.
Safety: manageable profile. Most common TRAEs = anemia, leukopenia, neutropenia & thrombocytopenia. Only 1.2% discontinued, no treatment-related deaths.
Conclusion: Early data suggest iza-bren may be a promising new option for EGFR-mutated NSCLC. A Phase III trial is ongoing in China.”
More Posts Featuring Iván González.